Premium
P1‐278: The efficacy of a medical food (Souvenaid ® ) in Alzheimer's disease: Results from the first trial and design of future trials
Author(s) -
Scheltens Philip,
Verhey Frans R.J.,
Olde Rikkert Marcel G.M.,
Kamphuis Patrick J.G.H.,
Wilkinson David,
Kurz Alexander
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.286
Subject(s) - medicine , disease , clinical trial , randomized controlled trial , pediatrics
of the ten patients we also recorded the electroencephalogram (EEG). EEG were recorded at T0 and at T1 for 5 five minutes through 21 electrodes following the 10-200 International System with a sampling frequency of 1024 Hz, a bandpass of 0,5-500 Hz, and a sensibility of 7 uV/mm. EEG were analyzed in the frequency domain (power spectrum and coherence). Results: AtDCS improved the accuracy of the word recognition task (p1⁄40.0068), CtDCS significantly worsened it (p1⁄40.011), and StDCS left it unchanged. tDCS left the visual attention RTs unchanged. AtDCS and CtDCS produced specific, differential, and significant effects over the mean power spectral density, the interand intra-hemispheric coherence in all the electrodes (p<0.0001). In particular, whereas AtDCS increased the occipital intra-hemispheric coherence in the gamma band (p1⁄40,047), CtDCS increased it in the d band (p1⁄40,021). Conclusions: tDCS delivered over the T-P cortex modulated cortical electrophysiological activity and improved a recognition memory task in patients with probable AD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom